Leerink Partners analyst Michael Cherny reiterated a Hold rating on Certara (CERT – Research Report) on April 11. The company’s shares closed ...

Leerink Partners analyst Michael Cherny maintained a Hold rating on Envista Holdings (NVST – Research Report) on April 10 and set a price ...

Fintel reports that on April 8, 2025, Leerink Partners initiated coverage of Spyre Therapeutics (NasdaqGS:SYRE) with a ...

Fintel reports that on April 2, 2025, Leerink Partners upgraded their outlook for Compass Therapeutics (NasdaqCM:CMPX) from Market Perform to Outperform. Analyst Price Forecast Suggests 419.11% Upside ...

J&J faces several headwinds at the start of the year, including patent expiry, talc litigation, and, now, tariffs.

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...

While J&J expects tariffs will cost it $400 million this year, the company maintained its earnings estimate and upped its ...

Trump could use the findings of the probe to impose certain trade restrictions on pharma products, including tariffs.

Despite President Donald Trump’s threat last week that tariffs on pharmaceuticals will come “very shortly,” the biopharma ...

Leerink analysts warned that Kennedy’s remarks to FDA staff would likely be a negative for the biotech industry.

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...

On Tuesday, Leerink Partners maintained its Outperform rating on CVS Health (NYSE:CVS) shares with a steady price target of $75.00. According to InvestingPro data, CVS Health, currently trading at ...